While Xeris Biopharma Holdings Inc has underperformed by -0.65%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, XERS rose by 74.71%, with highs and lows ranging from $3.64 to $1.69, whereas the simple moving average jumped by 21.43% in the last 200 days.
On November 11, 2024, Piper Sandler Downgraded Xeris Biopharma Holdings Inc (NASDAQ: XERS) to Neutral. A report published by Oppenheimer on March 28, 2024, Initiated its previous ‘Outperform’ rating for XERS. Craig Hallum also rated XERS shares as ‘Buy’, setting a target price of $4.50 on the company’s shares in an initiating report dated August 28, 2023. Jefferies Initiated an Buy rating on October 21, 2022, and assigned a price target of $4. Craig Hallum initiated its ‘Buy’ rating for XERS, as published in its report on April 28, 2022. SVB Leerink’s report from November 17, 2021 suggests a price prediction of $6 for XERS shares, giving the stock a ‘Outperform’ rating. H.C. Wainwright also rated the stock as ‘Buy’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Xeris Biopharma Holdings Inc (XERS)
Further, the quarter-over-quarter increase in sales is 12.31%, showing a positive trend in the upcoming months.
One of the most important indicators of Xeris Biopharma Holdings Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -617.16% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.29, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and XERS is recording 1.60M average volume. On a monthly basis, the volatility of the stock is set at 5.64%, whereas on a weekly basis, it is put at 4.30%, with a loss of -0.33% over the past seven days. Furthermore, long-term investors anticipate a median target price of $4.77, showing growth from the present price of $3.04, which can serve as yet another indication of whether XERS is worth investing in or should be passed over.
How Do You Analyze Xeris Biopharma Holdings Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 5.17%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 43.56% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
XERS shares are owned by institutional investors to the tune of 43.56% at present.
